Multicenter exploration of tenecteplase transition factors: A quantitative analysis

Tenecteplase (TNK) is gaining recognition as a novel therapy for acute ischemic stroke (AIS). Despite TNK offering a longer half-life, time and cost saving benefits and comparable treatment and safety profiles to Alteplase (ALT), the adoption of TNK as a treatment for AIS presents challenges for hos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of stroke and cerebrovascular diseases 2024-04, Vol.33 (4), p.107592-107592, Article 107592
Hauptverfasser:	Prasad, Sidarrth, Jones, Erica M., Gebreyohanns, Mehari, Kwon, Yoon, Olson, DaiWai M., Anderson, Jane A., Savitz, Sean I., Cruz-Flores, Salvador, Warach, Steven J., Rhodes, Charlotte E., Goldberg, Mark P., Ifejika, Nneka L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute ischemic stroke Alteplase Brain Ischemia - drug therapy Fibrinolytic Agents - adverse effects Humans Implementation science Ischemic Stroke - drug therapy Likert analysis Prospective Studies Stroke - diagnosis Stroke - drug therapy Tenecteplase Tenecteplase - adverse effects Thrombolytic Tissue Plasminogen Activator - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!